Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Abbott Laboratories (ABT)

Abbott to buy Exact Sciences for $105 per share in cash, about $21 billion in equity value

Mixed Impact 5 of 5 m&a Written later

Abbott agreed on November 19, 2025 to acquire Exact Sciences in a cash deal valued at about $21 billion in equity and $23 billion in enterprise value, with closing expected in the second quarter of 2026. Abbott said the deal is dilutive to adjusted earnings per share through 2027 and expects it to be accretive in 2028 and beyond, so the acquisition has a near-term cost to Abbott's per-share earnings.

Key points

  • Exact Sciences shareholders will receive $105 per common share in cash, subject to a shareholder vote and regulatory approvals.
  • Abbott's adjusted EPS impact is dilutive: ($0.20) in 2026 and ($0.16) in 2027, with accretion expected in 2028.
  • Abbott has a $20 billion senior unsecured bridge loan commitment from Morgan Stanley Senior Funding, Inc.
  • Abbott expects at least $100 million in annual pre-tax synergies by 2028 and an initial 2026 adjusted gross debt-to-EBITDA ratio of about 2.7x.

The filing

CompanyAbbott Laboratories (ABT)
Form8-K, current report
Filed with the SECNov 20, 2025, 7:37 AM ET
Accession number0001104659-25-114422

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 20, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.